Lactobacillus plantarum DT22 and application thereof in preparation of functional product for promoting discharge of microplastics

Abstract

The invention relates to the technical field of microorganisms, in particular to lactobacillus plantarum DT22 and application of the lactobacillus plantarum DT22 in preparation of functional products for promoting discharge of microplastics. The lactobacillus plantarum DT22 can produce various SCFAs at high yield, has the functions of promoting defecation and regulating immunity, can reduce microplastic residues in intestinal tracts, has good safety, can be widely applied to feed, food and medicine industries, and has wide application prospects.

Description

Technical Field

[0001] The present invention relates to the field of microbial technology, and in particular to a Lactobacillus plantarum DT22 and its application in the preparation of products with the function of promoting the excretion of microplastics. Background Art

[0002] Short-chain fatty acids (SCFAs) are a class of organic acids produced by the fermentation of intestinal bacteria, consisting of 1-6 carbon atoms. Among them, acetate, propionate, and butyrate have the highest contents, and the total amount exceeds 95% of the SCFA content. SCFAs are generated by the fermentation of indigestible food by the intestinal flora. Acetate can be produced by most intestinal bacteria, while propionate and butyrate are synthesized by specific bacteria.

[0003] It has been reported in the literature that SCFAs can provide energy for the intestinal flora and intestinal epithelial cells, promote the proliferation and differentiation of epithelial cells, and regulate the expression of tight junction proteins, thereby enhancing the intestinal barrier function, maintaining the structural stability of the intestinal flora, and the normal physiological functions of the intestine. SCFAs can also reduce the production of inflammatory factors such as interleukin-6 (IL-6), IL-8, IL-10, and tumor necrosis factor-α (TNF-α) by activating G protein-coupled receptors (GPCRs) in intestinal epithelial cells and immune cells, or by inhibiting the activity of histone deacetylases (HDACs), and play a role in reducing the inflammatory response in the intestinal mucosa. Therefore, as one of the important metabolites produced by the intestinal flora, SCFAs play an important role in regulating human health.

[0004] In the prior art, numerous strains producing SCFAs have been reported. However, these strains still have the defects of single function, poor safety, and low SCFA production. Therefore, exploring safe and efficient strains producing SCFAs remains a hot issue in this field.

[0005] In addition, probiotics are increasingly widely used to regulate intestinal health. A number of studies have shown that probiotics have a certain effect on improving constipation. For example, some studies have shown that taking a variety of probiotics can significantly reduce intestinal transit time and increase the frequency of defecation. Therefore, exploring new probiotics that can promote defecation is also one of the research hotspots in this field.

[0006] In recent years, microplastic pollution has also become a serious environmental problem and poses a potential threat to human health. Microplastics refer to tiny particles with a particle size less than 5 mm formed by the decomposition of plastic products discarded into the environment under physical, chemical, and biological actions. Their materials include polyethylene (PE), polypropylene (PP), polystyrene (PS), polyvinyl chloride (PVC), polyethylene terephthalate (PET), etc. Microplastics are widely present in air, water bodies, and soil, and can be ingested by plankton, fish, birds, etc., and ultimately enter the human body through the food chain. It is estimated that the weekly intake of microplastics by the human body can reach 5 g, and microplastics are present in human feces, blood, lung tissue, and placenta. A large number of studies have confirmed that microplastics can cause damage to the digestive system, respiratory system, immune system, nervous system, and reproductive system of rodents and aquatic organisms. The microplastics accumulated in tissues cannot be cleared, which can cause a large increase in reactive oxygen species, thereby causing oxidative stress and producing toxic effects. Therefore, removing microplastics from the human body and reducing the content of microplastics are of great significance for the long-term health of the human body.

[0007] Currently, there is no method to remove microplastics from the human body, and only a few reports have used biological methods to reduce plastic pollution in the environment and water bodies. For example, some bacteria and fungi can secrete cutinase, protease, esterase, lipase, etc. to decompose polymers into monomers or oligomers to achieve the purpose of degrading plastics; in addition, some bacteria have the ability to capture microplastics. They can attach to the surface of microplastics and form a viscous biofilm. This viscous matrix can capture free microplastics, resulting in the bioaccumulation of microplastics, thereby achieving the separation and removal of microplastics.

[0008] However, the existing bacteria or fungi that can degrade or adsorb microplastics are all non-edible strains, and such bacteria or fungi are also difficult to tolerate the gastrointestinal environment, so it is difficult to apply them to the removal of human microplastics. In order to reduce the accumulation of microplastics in the human body and reduce the health damage caused by microplastics to humans, there is a need in this field to discover probiotics that can tolerate the gastrointestinal environment and adsorb and remove microplastics. Summary of the Invention

[0009] The present invention provides a Lactiplantibacillus plantarum strain with high production of short-chain fatty acids, promotion of defecation, promotion of the excretion of microplastics from the body, and regulation of immune function. The specific invention content includes the following aspects.

[0010] First, the present invention provides a Lactiplantibacillus plantarum strain, which is Lactiplantibacillus plantarum DT22.

[0011] This strain was deposited at the Guangdong Microbial Culture Collection Center on July 5, 2023. Address of the depositary institution: 5th Floor, Building 59, No. 100 Yard, Middle Xianlie Road, Guangzhou; Postal Code: 510070. Taxonomic name: Lactiplantibacillus plantarum, Deposit number: GDMCC No: 63621.

[0012] This strain was isolated from pickled vegetables and has good acid and bile salt tolerance. After colonizing in animals, it can promote animal excretion and regulate immune function. Developing this strain into products such as edible probiotics can achieve the goals of accelerating defecation, promoting the excretion of microplastics from the body, enhancing immunity, and protecting the gastrointestinal tract.

[0013] Second, the present invention provides a microbial agent containing the above Lactiplantibacillus plantarum.

[0014] Third, the present invention provides a feed or feed additive containing the above Lactiplantibacillus plantarum or the above microbial agent.

[0015] Applying the Lactiplantibacillus plantarum DT22 of the present invention to feed can promote animal defecation, reduce the residual microplastics in the intestine, improve the intestinal health and immune status of animals, thereby promoting the healthy growth and development of animals.

[0016] Fourth, the present invention provides a medicine containing the above Lactiplantibacillus plantarum or the above microbial agent.

[0017] In some embodiments, the medicine is used for at least one of the following aspects:

[0018] (1) Increasing the content of short-chain fatty acids;

[0019] (2) Promoting defecation and / or reducing the residual microplastics in the intestine;

[0020] (3) Regulating immune function.

[0021] In some embodiments, the medicine uses Lactiplantibacillus plantarum DT22 or the above microbial agent as the active ingredient, and also includes pharmaceutically acceptable excipients.

[0022] In some embodiments, the excipients include but are not limited to fillers, excipients, lubricants, wetting agents, diluents.

[0023] Fifth, the present invention provides a food or food additive containing the above Lactiplantibacillus plantarum or the above microbial agent.

[0024] Preferably, the food is fermented milk.

[0025] Lactobacillus plantarum is one of the commonly used fermentation starters for preparing fermented milk. Lactobacillus plantarum DT22 of the present invention can be used alone or in combination with other strains in the preparation of fermented milk.

[0026] Sixthly, the present invention provides the use of the Lactobacillus plantarum or the microbial inoculant in the preparation of a product having the function of increasing the content of short-chain fatty acids.

[0027] Seventhly, the present invention provides the use of the Lactobacillus plantarum or the microbial inoculant in the preparation of a product having the function of promoting defecation and / or reducing the residual microplastics in the intestine.

[0028] Eighthly, the present invention provides the use of the Lactobacillus plantarum or the microbial inoculant in the preparation of a product having the function of regulating immune function.

[0029] The product includes drugs, feeds, feed additives, health products, foods, and food additives.

[0030] In the application of any of the above aspects, it includes the step of culturing Lactobacillus plantarum DT22.

[0031] Preferably, Lactobacillus plantarum DT22 is cultured using MRS medium.

[0032] Preferably, the MRS medium comprises the following components:

[0033] Casein peptone 10 g / L, beef extract powder 10 g / L, yeast extract powder 4 g / L, ammonium citrate 2 g / L, sodium acetate 5 g / L, magnesium sulfate 0.2 g / L, manganese sulfate 0.05 g / L, glucose 20 g / L, dipotassium hydrogen phosphate 2 g / L, and Tween 80 1 g / L. Preferably, pH = 5.7 ± 0.2.

[0034] Preferably, anaerobic culture is carried out at 37°C.

[0035] Preferably, the culture time is 24 h.

[0036] Lactobacillus plantarum DT22 of the present invention has the following microbiological characteristics:

[0037] (1) Morphological characteristics

[0038] Gram staining is positive. Under a light microscope, it is rod-shaped, with round ends, and can exist in pairs or in chains. After culturing on MRS solid medium for 24 h, round, convex in the middle, smooth at the edge, and bright milky white colonies are formed.

[0039] (2) Physiological characteristics

[0040] Lactobacillus plantarum DT22 can grow in acidic or bile salt-containing media. After colonizing in animals, it can promote excretion, regulate immunity, and reduce the residual microplastics in the intestine.

[0041] Lactobacillus plantarum is widely present in fermented foods and has applications as a starter and preservative in the food industry. Lactobacillus plantarum has been included in the list of strains that can be used in foods. It has also obtained the GRAS (generally recognized as safe) certification from the US Food and Drug Administration (FDA) and is included in the Qualified Presumption of Safety (QPS) list promulgated by the European Food Safety Authority (EFSA). It is widely used in various probiotic foods and dietary supplements globally. Genomic research data, mouse experiments, and human clinical trials have all proven the safety of Lactobacillus plantarum.

[0042] Compared with the prior art, the beneficial effects of the present invention are as follows:

[0043] The Lactobacillus plantarum DT22 of the present invention can produce high yields of various SCFAs, and at the same time has the functions of promoting defecation, regulating immunity, and reducing the residual microplastics in the intestine. Moreover, it has good safety and can be widely used in the feed, food, and pharmaceutical industries, with broad application prospects. Description of the Drawings

[0044] Figure 1 It is a colony morphology diagram of Lactobacillus plantarum DT22 on MRS medium.

[0045] Figure 2 It is a microscopic examination diagram of Lactobacillus plantarum DT22.

[0046] Figure 3 It is a statistical chart of the survival rate of Lactobacillus plantarum DT22 in acidic medium. ns indicates that the p-value is greater than 0.05. The data are from three repeated experiments, and the error bars represent the standard deviation.

[0047] Figure 4 It is a statistical chart of the survival rate of Lactobacillus plantarum DT22 in bile salt-containing medium. ns indicates that the p-value is greater than 0.05. The data are from three repeated experiments, and the error bars represent the standard deviation.

[0048] Figure 5 It is a statistical chart of the concentrations of acetic acid and propionic acid in the fermentation broth of Lactobacillus plantarum DT22. The error bars represent the standard deviation. The data are from three repeated experiments. The statistical analysis method is t test, and **** indicates that the p-value is less than 0.0001.

[0049] Figure 6 It is a diagram for measuring the activated carbon transport rate after colonizing Lactobacillus plantarum DT22.

[0050] Figure 7 Determination of the content of IL-4 in serum after colonization with Lactiplantibacillus plantarum DT22. Error bars represent standard deviation. Data are from three replicate experiments. The statistical analysis method is t test. *** indicates a p-value less than 0.001.

[0051] Figure 8 Detection of the residual amount of PS fluorescent microspheres in the colon of mice. Error bars represent standard deviation. The statistical analysis method is ANOVA. ** indicates a p-value less than 0.01, and **** indicates a p-value less than 0.0001. Detailed implementation manners

[0052] To make the objectives, technical solutions and advantages of the present invention clearer, the technical solutions in the present invention will be clearly and completely described below. Obviously, the described embodiments are some, but not all, of the embodiments of the present invention. All other embodiments obtained by those of ordinary skill in the art without making creative efforts based on the embodiments in the present invention belong to the scope of protection of the present invention.

[0053] For those not specified in the embodiments regarding specific techniques or conditions, they are all conventional methods or are carried out according to the techniques or conditions described in the literature in this field, or according to the product specifications. For those reagents and instruments etc. not specified regarding the manufacturer, they are all conventional products that can be obtained through regular channels.

[0054] The trace element solution and vitamin solution in the in vitro simulated intestinal environment culture medium formula are both purchased from Coolaber Company. The product number of the trace element solution is SL0120, and the product number of the vitamin solution is SL0110.

[0055] Example 1 Isolation and identification of Lactiplantibacillus plantarum DT22

[0056] 1. Isolation and identification of Lactiplantibacillus plantarum DT22

[0057] 1.1 Sample source

[0058] The strain Lactiplantibacillus plantarum DT22 used in this example was isolated from pickled Chinese cabbage.

[0059] 1.2 Preparation of culture medium

[0060] The culture medium used for sample isolation is GAM medium, and the culture medium for Lactiplantibacillus plantarum DT22 is MRS medium.

[0061] The components of GAM medium are shown in Table 1, and the pH value of GAM medium is 7.3 ± 0.1; the components of MRS medium are shown in Table 2, and the pH value of MRS medium is 5.7 ± 0.2; adding 1.5% agar makes it a solid medium.

[0062] Table 1 GAM Medium Formula

[0063]

[0064] Table 2 MRS Medium Formula

[0065]

[0066]

[0067] 1.3 Isolation of Strains

[0068] Put 1 g of pickled Chinese cabbage into 10 mL of the GAM liquid medium prepared in step 1.2, mix well and culture at 36 °C for 24 h. Then, in a laminar flow hood, aspirate 1 mL of the enrichment solution, perform ten-fold serial dilution, and select 10 -4 、10 -5 、10 -6 、10 -7 Apply 100 μL of the bacterial solutions at four dilution gradients to the culture dishes containing sterile GAM solid medium, and statically culture at 36 °C under anaerobic conditions for 48 h - 72 h. After obvious single colonies are formed, use a high-throughput automated platform to automatically pick typical colonies from the culture dishes into the GAM liquid medium for culture. The isolated strains are identified by 16S rRNA sequencing to determine the species information.

[0069] 2 Identification of Lactobacillus plantarum DT22

[0070] 2.1 Colony Characteristics

[0071] After Lactobacillus plantarum DT22 is cultured in MRS solid medium for 24 h, it forms round, convex in the middle, smooth and neat at the edge, and milky white colonies with a moist surface, as shown in Figure 1 .

[0072] 2.2 Morphology under Microscope

[0073] Colony smear of Lactobacillus plantarum DT22: Gram staining is positive. Under a light microscope, the cells are rod-shaped, round at both ends, and single cells are arranged in pairs or in chains, as shown in Figure 2 .

[0074] 2.3 16S rRNA Identification

[0075] Identification unit: Tsingke Biotechnology Co., Ltd.

[0076] The identification sequence is shown in SEQ ID No.1.

[0077] Identification result: The sequencing results were compared with the NCBI database, and combined with the physiological and biochemical results, the strain was identified as Lactiplantibacillus plantarum.

[0078] Example 2 Acid tolerance detection of Lactiplantibacillus plantarum DT22

[0079] The overall pH condition in the human gastric environment is strongly acidic. Therefore, the acid tolerance ability of the strain is an important indicator to evaluate whether it can survive and colonize in the gastric acid environment. The commercial strain Lactobacillus rhamnosus GG is a probiotic widely used at present and has strong acid tolerance ability.

[0080] In this example, MRS medium with pH = 2.5 was used to verify the acid tolerance ability of Lactiplantibacillus plantarum DT22. The specific steps are as follows:

[0081] Take 1 mL of the bacterial solution, centrifuge at 4000 rpm for 10 min, discard the supernatant, then add 1 mL of PBS to wash once, after centrifuging at 4000 rpm for 10 min, resuspend the precipitate with MRS medium with pH = 2.5. Incubate at 37 °C for 3 h, and sample at 0 h and 3 h respectively. After centrifuging the samples, resuspend them with PBS and dilute them in gradients. The diluted samples are spread on MRS agar plates and anaerobically cultured at 37 °C for 16 h, and then colony counting is carried out. The survival rate calculation formula is: Acid tolerance survival rate (%) = C1 / C0 × 100% (C0: counting result at 0 h; C1: counting result at 3 h). The control strain is Lactobacillus rhamnosus LGG.

[0082] After 3 hours of culture in the acidic medium, the survival rate of the control strain Lactobacillus rhamnosus LGG was 84.56%, and the survival rate of Lactiplantibacillus plantarum DT22 was 68.24% ( Figure 3 ), which was not significantly different from the control strain, indicating that the strain can survive in the gastric environment.

[0083] Example 3 Bile salt tolerance detection of Lactiplantibacillus plantarum DT22

[0084] After bacteria enter the intestine through the stomach, the high concentration of bile salts in the small intestine will kill the bacteria. The residence time of food in the small intestine is generally 1 - 4 h.

[0085] In this example, 0.1% bile salt - MRS medium was used to verify the bile salt tolerance performance of Lactiplantibacillus plantarum DT22 strain. The specific steps are as follows:

[0086] Inoculate the Lactobacillus plantarum DT22 bacterial solution into a 96-deep well plate containing MRS medium and culture anaerobically at 37 °C for 24 h. Take 300 μL of the cultured bacterial solution, centrifuge at 4000 rpm for 10 min, discard the supernatant, add 600 μL of MRS medium containing 0.1% bile salt, and resuspend and mix well. For the control group, take 100 μL of the resuspended solution and add 20 μL of MTT (thiazole blue) solution; for the treatment group, take 100 μL of the resuspended solution, incubate at 37 °C for 4 h, and then add 20 μL of MTT solution. After adding the MTT solution, react in the dark at 37 °C for 4 h. After the reaction, centrifuge at 4000 rpm for 10 min and discard the supernatant. Add 100 μL of DMSO solution to each well, incubate at 37 °C with shaking for 10 min to completely dissolve and mix the purple formazan produced by the reaction. After mixing, measure the absorbance of the solution at 570 nm with an enzyme-linked immunosorbent assay (ELISA) reader and calculate the survival rate. Survival rate = A1 / A0 × 100% (A1: absorbance value of the treatment group solution at 570 nm, A0: absorbance value of the control group solution at 570 nm). Measure the survival rate of the control strain Lactobacillus rhamnosus LGG using the same method.

[0087] After 4 h of culture in 0.1% bile salt-MRS medium, the survival rate of the control strain Lactobacillus rhamnosus LGG was 101.5%, and the survival rate of Lactobacillus plantarum DT22 was 109.8% ( Figure 4 ). This indicates that Lactobacillus plantarum DT22 has the same bile salt tolerance as the control strain Lactobacillus rhamnosus LGG and can survive in the small intestine.

[0088] Example 4 Detection of the SCFA-producing ability of Lactobacillus plantarum DT22

[0089] To better verify the SCFA-producing ability of Lactobacillus plantarum DT22 in vivo, an in vitro simulated intestinal environment medium was used in this example, and the medium formula is shown in Table 3. Inoculate Lactobacillus plantarum DT22 into this medium and culture anaerobically at 37 °C for 24 h. Take the culture solution, centrifuge at 4000 rpm for 10 min, filter the supernatant through a 0.22 μm aqueous filter membrane and add it to a liquid phase vial, and detect the SCFA content in the supernatant by HPLC. The control strain is another Lactobacillus plantarum obtained in the same batch of screening experiments.

[0090] From Figure 5 It can be seen that the contents of acetic acid and propionic acid in the fermentation broth of Lactobacillus plantarum DT22 are significantly higher than those of the control strain. Therefore, Lactobacillus plantarum DT22 is a high-yield SCFA strain isolated in this study. Since the glucose content of the in vitro simulated intestinal environment medium used in this example is significantly lower than that of common microbial media such as MRS medium, the contents of acetic acid and propionic acid produced by Lactobacillus plantarum DT22 will be relatively low. If a common microbial medium is used, higher yields of acetic acid and propionic acid can be expected.

[0091] Table 3 Formula of in vitro simulated intestinal environment culture medium

[0092]

[0093]

[0094] Example 5 Lactobacillus plantarum DT22 promotes mouse excretion

[0095] Six-week-old male C57 mice that had been adaptively fed for one week were randomly divided into two groups. The experimental group of mice (6 mice) were gavaged with Lactobacillus plantarum DT22, and the control group of mice were gavaged with the commercial strain Lactobacillus rhamnosus GG. The gavage days were 7 days, and the gavage dose was 10 9 CFU / day. Twenty-four hours after the last gavage of probiotics, all mice were gavaged with 2 ml of 5% activated carbon. Twenty minutes after the gavage of activated carbon, the mice were sacrificed, the abdominal cavity was dissected, the intestine from the pylorus to the ileocecal region was taken out and placed on paper, and the position of activated carbon transport was measured under the condition that the intestine was fully relaxed. After the measurement was completed, the colon tissue was stored at -80 °C for ELISA detection.

[0096] From Figure 6 It can be seen that compared with the colonization of Lactobacillus rhamnosus GG, the colonization of Lactobacillus plantarum DT22 accelerated the transport rate of activated carbon and better promoted mouse excretion.

[0097] Example 6 Lactobacillus plantarum DT22 regulates mouse immunity

[0098] The ileum tissue samples preserved in Example 5 were taken for ELISA detection and analysis.

[0099] The results are as Figure 7 shown. Compared with the colonization of Lactobacillus rhamnosus GG, the gavage of Lactobacillus plantarum DT22 significantly increased the level of the cytokine interleukin-4 (IL-4) in the serum, which indicates that the colonization of Lactobacillus plantarum DT22 has a better effect of activating immunity than the colonization of Lactobacillus rhamnosus GG.

[0100] Example 7 Gavage of Lactobacillus plantarum DT22 reduces microplastic residues in vivo

[0101] Six-week-old C57 mice were purchased. After one week of adaptive feeding, the experimental group of mice were gavaged with 1 mg of PS fluorescent microspheres (10 mg / mL, particle size 5 μm, BESLER company) every day, and at the same time were gavaged with 1*10 9CFU Lactobacillus plantarum DT22, mice in the control group were gavaged with 1 mg of PS fluorescent microspheres every day, and at the same time, an equal volume of normal saline was gavaged every day. Mice in the blank control group (NC) were not gavaged with PS fluorescent microspheres and were only gavaged with an equal volume of normal saline. Gavage was continued for 7 days. After the last gavage of PS fluorescent microspheres, the mice were deprived of water and food for 16 h, then sacrificed, and the intestinal tissues of the mice were dissected to detect the residual amount of PS fluorescent microspheres. The detection method was as follows: Take the colon tissue of the mice: After weighing, add 400 μL of lysis buffer (23 g / L Na2HPO4, 4.6 g / L NaH2PO4), grind it with a tissue grinder (60 Hz, 45 s, 4 steel beads of 2 mm), after grinding, add 40 μL of 50 g / L SDS and mix well by shaking, then add 40 μL of Protein K (20 mg / mL). Incubate overnight at 37 °C, dilute with 400 μL of lysis buffer, suck the homogenate with a 1 mL syringe, and filter it through a 100 μm cell strainer into a 1.5 mL EP tube. Take 200 μL of the filtrate into a 96-well plate and detect the fluorescence microsphere signal with a flow cytometer. The detection parameters of the flow cytometer were FSC greater than 60000, the sample volume was 20 μL, and the detection channels were: B530, FITC-H.

[0102] The results are as Figure 8 shown. There were a large number of PS fluorescent microsphere residues in the colon of the control group mice, and gavage with Lactobacillus plantarum DT22 significantly reduced the residual amount of PS fluorescent microspheres in the colon of the mice. This indicates that gavage with Lactobacillus plantarum DT22 reduced the residue of microplastics in the mice.

[0103] In summary, the Lactobacillus plantarum DT22 isolated and screened in the present invention can tolerate acid and bile salts, has the ability to colonize in the stomach and small intestine, and can be applied to the development of edible probiotics. Lactobacillus plantarum DT22 has the ability to produce a variety of SCFAs in high yields. After colonizing in the mice, it can increase the intestinal transport rate of the mice, promote the excretion of the mice, promote the excretion of microplastics from the body, and at the same time has the effect of regulating immunity and has a protective ability for the host. Thus, it can be seen that Lactobacillus plantarum DT22 is a strain suitable for the digestive tract environment and has broad application prospects in promoting host excretion, reducing the residue of microplastics in the intestine, and regulating immunity.

[0104] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention and are not intended to limit them; although the present invention has been described in detail with reference to the foregoing embodiments, those of ordinary skill in the art should understand that they can still modify the technical solutions recorded in the foregoing embodiments, or perform equivalent replacements for some of the technical features; and these modifications or replacements do not make the essence of the corresponding technical solutions deviate from the spirit and scope of the technical solutions of the various embodiments of the present invention.

Claims

1. A Lactobacillus plantarum, characterized in that, It is Lactiplantibacillus plantarum DT22, and its deposit number is GDMCC No: 63621.

2. A microbial inoculum containing the Lactiplantibacillus plantarum described in claim 1.

3. A feed or feed additive containing the Lactiplantibacillus plantarum described in claim 1 or the microbial inoculum described in claim 2.

4. A medicine containing the Lactiplantibacillus plantarum described in claim 1 or the microbial inoculum described in claim 2.

5. The medicine according to claim 4, characterized in that, The medicine is used for at least one of the following aspects: (1) Increasing the content of short-chain fatty acids; (2) Promoting defecation and / or reducing the residual microplastics in the intestine; (3) Regulating immune function.

6. A food or food additive containing the Lactiplantibacillus plantarum described in claim 1 or the microbial inoculum described in claim 2.

7. Use of the Lactiplantibacillus plantarum described in claim 1 or the microbial inoculum described in claim 2 in the preparation of a product with the function of increasing the content of short-chain fatty acids.

8. Use of the Lactiplantibacillus plantarum described in claim 1 or the microbial inoculum described in claim 2 in the preparation of a product with the function of promoting defecation and / or reducing the residual microplastics in the intestine.

9. Use of the Lactiplantibacillus plantarum described in claim 1 or the microbial inoculum described in claim 2 in the preparation of a product with the function of regulating immune function.

10. The application according to any one of claims 7 to 9, characterized in that, It includes the step of culturing the Lactiplantibacillus plantarum described in claim 1.

Images